Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma

 Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma

Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma

Shots:

  • The sBLA is based on P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a ratio 2:1 with unresectable HCC prior not treated with systemic therapies
  • The P-III IMbrave150 study results: 42% reduction in risk of death; 41% reduction in risk of disease worsening or death; safety profile is consistent with the individual therapies, presented at ESMO201
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptor. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity, by inhibiting VEGF related immunosuppression

Click here ­to­ read full press release/ article | Ref: Roche | Image: Behance

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post